Key result
Menopause transition is linked to ~127% higher risk of elevated Lp(a) in intermediate-risk women.
Why the study?
Changes in Lp(a) levels and transitions across ASCVD risk thresholds by menopausal trajectory were not well characterized to inform risk stratification and testing recommendations.
Does transitioning through menopause increase the risk of crossing ASCVD risk-enhancing Lp(a) thresholds in women?
Cohort (n=4,562)
Yes
Does transitioning through menopause increase the risk of crossing ASCVD risk-enhancing Lp(a) thresholds in women?
Answers are grounded in this paper and cite their sources.
Women with intermediate Lp(a) levels may cross risk-enhancing thresholds during the menopausal transition, suggesting that a single lifetime measurement may be insufficient for accurate risk stratification.
Aim Assess changes in Lp(a) levels and transitions across ASCVD risk-thresholds by menopausal trajectory to inform risk stratification and testing recommendations. Methods We examined changes in Lp(a) between visits 1 and 2 among UK Biobank women. Analyses were examined by menopausal trajectory: those who underwent menopause (N=415), those who remained premenopausal (N=532), and those who remained postmenopausal (N=3,615) between visits. Change in Lp(a) between visits was also stratified by visit 1 Lp(a). The primary outcome was incident Lp(a) ≥125 nmol/L at visit 2, estimated using Poisson regression. Results Data were available for 4,562 women (mean visit 1 age = 57 years; median visit 1 Lp(a) = 22 nmol/L; median time between visits = 4 years). At visit 1, median Lp(a) was 23 nmol/L in postmenopausal women and 19 nmol/L in premenopausal women. Overall, median changes in Lp(a) between visits were modest. Among women with intermediate visit 1 Lp(a) (75-125 nmol/L), those who transitioned through menopause experienced a median increase of 34.9 nmol/L, approximately fourfold greater than women who remained pre- or postmenopausal. Further, 22 of 39 (56%) of women with intermediate visit 1 Lp(a) who had menopause between visits had incident Lp(a) ≥125 nmol/L at visit 2, compared with 29% and 28% of women who remained pre- or postmenopausal, representing a risk ratio of 2.27 (95% CI: 1.36, 3.78) after adjustment for visit 1 age and continuous Lp(a). Conclusions Relying on a single lifetime Lp(a) measurement may miss reclassification across risk-enhancing thresholds during menopause, particularly for women with intermediate premenopausal levels.
No takes yet. Share an insight, caveat, or question.
Palmer et al. (2026) conducted a cohort in Elevated Lipoprotein(a) (n=4,562). Menopausal transition vs. Remaining premenopausal or postmenopausal was evaluated on incident Lp(a) ≥125 nmol/L at visit 2 (RR 2.27, 95% CI 1.36-3.78).
Synapse has enriched 10 related papers. Consider them for comparative context: